

Reference number
1940-H

SPECIALTY QUANTITY LIMIT PROGRAM

TYSABRI (natalizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tysabri (natalizumab) 300mg/15mL vial	15 mL per 28 days	Multiple Sclerosis 300 mg every four weeks Crohn's Disease 300 mg every four weeks

III. REFERENCE

1. Tysabri [package insert]. Cambridge, MA: Biogen Inc.; August 2019.